TKT and B-cell chronic lymphocytic leukemia: The first-in-class ROR1 inhibitor (KAN0439834), which binds to the intracellular tyrosine kinase (TK) domain of ROR1, induced apoptosis of CLL cells and inhibited tumor cell growth in NOD/SCID mice xenotransplanted with human CLL cells [46].